Trials / Withdrawn
WithdrawnNCT06055374
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of BxC-I17e Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Brexogen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of a multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BxC-I17e | Pharmaceutical form : solution for injection |
| DRUG | Placebo | Pharmaceutical form : solution for injection |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-04-30
- Completion
- 2025-08-30
- First posted
- 2023-09-26
- Last updated
- 2024-08-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06055374. Inclusion in this directory is not an endorsement.